Table 4.
The m6A protein alterations are correlated with clinicopathological features
Cancer | Regulator | Alteration | Prognosis | Metastasis/Invasion | Tumor size | Tumor stage | Histological grade | Recurrence | Therapy | Refs |
---|---|---|---|---|---|---|---|---|---|---|
AML | METTL3/ WTAP | Overexpression | Poor | [41, 43] | ||||||
AML | METTL3/METTL14/YTHDF1/YTHDF2/FTO/ALKBH5 | Mutation | Poor | [142] | ||||||
GBM | METTL3 | Overexpression | Poor | Radioresistance | [48] | |||||
GBM | WTAP/RBM15/YTHDF1/ ALBKH5 | Overexpression | Poor | Increase | [49] | |||||
LC | METTL3 | Overexpression | Poor | Lymph node metastasis Brain metastasis | Increase | Worsen | [54, 55] | |||
LC | FTO/ IGF2BP1 | Overexpression | Poor | [56, 59] | ||||||
HCC | METTL3/YTHDF1 | Overexpression | Poor | Worsen | [58, 121] | |||||
HCC | KIAA1429/ IGF2BP1 | Overexpression | Poor | [59, 63] | ||||||
HCC | WTAP | Overexpression | Poor | Prone | [64] | |||||
HCC | METTL14 | Down-regulation | Better | Weaken | Decrease | [100] | ||||
HCC | YTHDF2 | Overexpression | Poor | Microvascular invasion | Worsen | [65] | ||||
CRC | METTL3 | Overexpression | Poor | Lymph node metastasis Liver metastasis Distant metastasis | Prone | Chemotherapy resistance | [67, 68, 70] | |||
CRC | METTL3 | Down-regulation | Better | Decrease | [103] | |||||
CRC | METTL14 | Down-regulation | Better | Weaken | Decrease | [104] | ||||
CRC | FTO | Overexpression | Poor | Increase | Worsen | [71] | ||||
CRC | YTHDC2 | Overexpression | Poor | Lymph node metastasis | Worsen | [74] | ||||
CRC | YTHDF1 | Overexpression | Poor | Lymph node metastasis Distant metastasis | Worsen | [75] | ||||
CRC | IGF2BP2 | Overexpression | Poor | [77] | ||||||
PDAC | METTL3 | Overexpression | Poor | Worsen | [78] | |||||
GC | METTL3 | Overexpression | Poor | [80] | ||||||
BCA | METTL3 | Overexpression | Poor | Worsen | Increase | [82] | ||||
BCA | METTL14 | Down-regulation | Better | Weaken | [106] | |||||
PCA | YTHDF2 | Overexpression | Poor | Increase | [85] | |||||
RCC | METTL3 | Down-regulation | Better | Decrease | Decrease | [107] | ||||
RCC | FTO | Down-regulation | Better | Weaken | [108] | |||||
RCC | WTAP | Overexpression | Poor | Increase | Worsen | [87] | ||||
CSCC | FTO | Overexpression | Poor | Worsen | Increase | [88] | ||||
BC | METTL3 | Overexpression | Poor | [143] | ||||||
BC | FTO | Overexpression | Poor | Increase | [94] | |||||
EOC | METTL3 | Overexpression | Poor | Worsen | Increase | [95] | ||||
EOC | ALKBH5 | Overexpression | Poor | Worsen | Increase | [96] | ||||
EOC | IGF2BP1 | Overexpression | Poor | [59] | ||||||
Melanoma | FTO | Overexpression | Poor | Worsen | [97] | |||||
Melanoma | YTHDF1 | Down-regulation | Better | Weaken | [110] |
AML acute myeloid leukemia; GBM glioblastoma; LC lung cancer; HCC hepatocellular carcinoma; CRC colorectal cancer; PDAC pancreatic cancer; GC gastric carcinoma; BCA bladder cancer; PCA prostate cancer; RCC renal cell carcinoma; CSCC cervical squamous cell carcinoma; BC breast cancer; EOC epithelial ovarian cancer